SuperworthMeiraGTx MGTX
- Market cap
- $884.6M
- PE
- 13.0×
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 2.2×
- EV/EBIT
- 4.6×
- Revenue, 12 months
- $397.5M
- growth n/m, growth from a base too small to compare
- Net margin
- 19.9%
- Free cash flow yield
- 1.2%
MeiraGTx trades at 13.0× trailing earnings. Revenue was $397.5M over the last twelve months with a 20% net margin.
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $5.1M+6% | $2M | $697K−79% | $282K−92% | $10.9M+114% | $21.4M+949% | $1.9M+176% | $3.7M+1209% | $410K−96% | $75.4M+252% | $293K−85% | $321.4M+8609% | |
| Cost of revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $2.7M | n/a | n/a | n/a | $7.2M+168% |
| Gross profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $1M | n/a | n/a | n/a | $314.3M+30863% |
| R&D | $27.9M+65% | $33.7M+55% | $34.3M+54% | $34.9M+75% | $26.2M−6% | $24M−29% | $32.8M−5% | $33.5M−4% | $32.5M+24% | $30.8M+29% | $32M−2% | $57.8M+73% |
| SG&A | $10M−7% | $12.1M−13% | $13.1M+3% | $11.3M−9% | $24.7M+147% | $28.9M+138% | $10.7M−18% | $12.3M+9% | $13.9M−44% | $18.1M−37% | $9.1M−15% | $12M−2% |
| −$32.8M+44% | −$43.8M+7% | −$46.8M+47% | −$45.9M+60% | −$40M+22% | −$31.5M−28% | −$41.6M−11% | −$44.8M−2% | −$46.1M+15% | $26.5M | −$40.8M−2% | $244.4M | |
| Interest expense | $3.4M+79% | $3.4M+19% | $3.3M+6% | $3.3M−3% | $3.4M−1% | $3.4M−1% | $3M−6% | $3M−7% | $3.1M−9% | $3.1M−10% | $2.8M−6% | $3.5M+16% |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | $2.4M | |
| Net income | −$44.3M+19% | $20.2M | −$20.4M−33% | −$48.6M+64% | −$39.3M−11% | −$39.4M | −$40M+96% | −$38.8M−20% | −$50.5M+28% | $15.1M | −$46.3M+16% | $160.7M |
| −$0.74−11% | $0.32 | −$0.32−48% | −$0.76+43% | −$0.55−26% | −$0.50 | −$0.51+59% | −$0.48−37% | −$0.62+13% | $0.19 | −$0.57+12% | $1.71 | |
| 59.5M+33% | 62.2M+33% | 64.1M+32% | 64.4M+16% | 71.6M+20% | 79.1M+27% | 79M+23% | 80.6M+25% | 80.9M+13% | 81.1M+3% | 81.3M+3% | 93.8M+16% |
Gross profit: Q2 FY25 and Q2 FY26: not printed by the filing, worked out from its own lines.
R&D: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
SG&A: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Operating income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Interest expense: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
Pre-tax income: Q1 FY18: 6 months less the 3 months printed beside them.
Net income: Q1 FY17 and Q1 FY18: 6 months less the 3 months printed beside them.
EPS, diluted: 11 periods, Q1 FY17 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: Q1 FY17: share-days: the 6-month average less the second quarter's. 7 periods, Q4 FY17 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. Q4 FY23 and Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Biotechnology nearest MeiraGTx's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MGTXMeiraGTx | $884.6M | 13.0× | 18.0× | 2.2× | n/m | 19.9% | |
| VCELVericel | $2.2B | 92.5× | 158× | 7.1× | +23% | 7.9% | |
| ADMAAdma Biologics | $2.4B | 15.3× | 21.5× | 4.7× | +8% | 33.0% | |
| PLXProtalix BioTherapeutics | $205.5M | 11.1× | 34.2× | 2.5× | +30% | 23.5% | |
| Peer median | $2.2B | 15.3× | 34.2× | 4.7× | +23% | 23.5% |
More on MeiraGTx
Each number over time
- PE ratio
- Price to sales ratio
- Price to free cash flow
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Shares outstanding
Where it ranks
- #10of 202Healthcare stocks with the lowest EV/EBIT
- #1of 17Biotech stocks with the lowest EV/EBIT
- #2of 16Biotech stocks with the lowest PE ratio
- #8of 63Biotech stocks with the lowest price to sales ratio
Its groups
About
- Industry
- Biotechnology
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .